Goblet cell adenocarcinoma (GCA) is a cancer that develops almost exclusively in the appendix. GCA is extremely rare, affecting only a very small number of people each year.
GCA is unusual because it has features that overlap with neuroendocrine tumours and adenocarcinomas. This means the tumour contains mucus-producing goblet-like cells and may also show neuroendocrine features when examined under the microscope..
Because of this mixed biology, GCA does not usually behave like a typical slow-growing appendiceal neuroendocrine tumour. It is usually more aggressive and is generally treated more like an appendiceal adenocarcinoma.
GCA was previously called goblet cell carcinoid or adenocarcinoid, but these older terms are no longer preferred because they can make the disease sound less aggressive than it may be.
Due to its rarity and complexity, people diagnosed with GCA should have their case reviewed by a multidisciplinary team (MDT) with experience in appendix cancers and neuroendocrine cancers.
GCA starts in the appendix, a small pouch attached to the beginning of the large bowel.
Under the microscope, the tumour contains mucus-secreting goblet-like cells as well as neuroendocrine features. Pathologists may use special staining to assess glandular and neuroendocrine marker expression and help distinguish GCA from other appendix tumours.
Although GCA has neuroendocrine features, it is classified, staged and treated differently from classic appendiceal neuroendocrine tumours. This is because GCA is more likely to invade nearby tissue, spread to lymph nodes, and spread within the abdominal cavity.
One of the most common sites for GCA to spread (metastasise) is the lining of the abdomen, known as the peritoneum.
GCA often does not cause specific symptoms in the early stages.
Many cases are discovered after surgery for suspected appendicitis. This happens because the tumour can block the appendix and cause inflammation, pain, or infection.
Symptoms may include:
In women, symptoms may be related to ovarian spread. This can sometimes lead to an initial suspicion of ovarian cancer before further testing identifies the appendix as the primary site.
GCA is often diagnosed after the appendix has been removed for suspected appendicitis.
Diagnosis requires examination of the tumour under a microscope. Pathology is essential because GCA can be difficult to distinguish from other appendix cancers, ovarian cancers, and classic neuroendocrine tumours.
Tests may include:
Accurate diagnosis matters because GCA is not managed the same way as a typical appendiceal NET.
GCA is graded based on how the tumour cells look under the microscope, including the proportion of low-grade and high-grade tumour patterns.
The grade helps describe how aggressive the cancer may be. Higher-grade tumours are more likely to grow quickly and spread.
GCA is also staged in a similar way to appendiceal adenocarcinoma. Staging looks at:
This information helps guide decisions about surgery, chemotherapy, and follow-up.
Treatment usually involves surgery and may also include chemotherapy.
The exact treatment plan depends on the tumour stage, grade, whether lymph nodes are involved, and whether the cancer has spread.
For many people, treatment involves a right hemicolectomy. This surgery removes the appendix, the right side of the colon, and nearby lymph nodes.
This is done because GCA has a higher risk of lymph node spread than many classic appendiceal NETs. Removing nearby lymph nodes also helps with accurate staging.
In many cases, a right hemicolectomy is recommended because GCA can behave more aggressively than it may initially appear. However, management should be individualised, especially for very early-stage or lower-risk disease. Specialist review is strongly advised before considering whether appendectomy alone is sufficient.
Chemotherapy may be recommended after surgery, especially if the tumour is higher grade, lymph nodes are involved, or the cancer has spread.
Chemotherapy is usually based on regimens used for bowel or appendiceal adenocarcinoma rather than typical NET treatment.
If GCA has spread within the abdominal cavity, more complex treatment may be considered.
This may include cytoreductive surgery (CRS), which aims to remove visible tumour deposits, sometimes combined with heated chemotherapy delivered directly into the abdominal cavity, a technique known as hyperthermic intraperitoneal chemotherapy (HIPEC). Together, this combined approach is called CRS/HIPEC.
Not everyone is suitable for this treatment. Decisions depend on the extent of disease, overall health, tumour biology, and specialist centre assessment and availability.
GCA can be confusing because it has neuroendocrine features, but it is not treated like a typical appendiceal neuroendocrine tumour.
Classic appendiceal NETs are often small, slow-growing, and found incidentally after appendectomy. Many have an excellent prognosis and may not require further treatment if low-risk features are present.
GCA is different because it:
This distinction is important for patients, families, and healthcare teams.
A diagnosis of GCA can be difficult because the disease is rare and often unexpected.
Many people are diagnosed after what they thought was routine appendicitis. Others may have already had symptoms for some time or may be diagnosed after investigation of abdominal or ovarian masses.
Living with GCA may involve:
Because GCA is uncommon, it is reasonable to ask whether your case has been reviewed by a specialist multidisciplinary team with experience in appendix cancers.
Follow-up is important after treatment for GCA.
The follow-up plan may include:
The timing and intensity of follow-up depends on the tumour grade, stage, treatment received, and individual risk factors.
Research into GCA is ongoing.
Important areas of study include:
Because GCA is rare, clinical trial options may be limited, but specialist centres may be able to advise whether any research studies or advanced treatment pathways are available.
Goblet cell adenocarcinoma can be hard to understand because it has overlapping features and has historically been described using several different names. It has neuroendocrine marker expression, but it often behaves more like an adenocarcinoma.
NeuroEndocrine Cancer Australia can help people affected by GCA access information, support, and guidance on questions to ask their treating team.
NECA provides:
If you or someone you care for has been diagnosed with GCA, support is available.
Help 31,000+ neuroendocrine cancer patients get the specialised care they deserve.
Every dollar raised is fully tax deductible and helps fund much needed advocacy efforts and patient support.
